NCT06414590 2026-03-03
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT05524935 2026-01-08
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07276386 2025-12-11
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03467516 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT06932757 2025-06-03
Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT05077280 2022-12-06
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
Phase 2 Recruiting